Cargando…
Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment
T cell lymphoma (TCL) is a highly heterogeneous group of diseases with a poor prognosis and low 5-year overall survival rate. The current therapeutic regimens have relatively low efficacy rates. Clinical studies of single-target chimeric antigen receptor T cell (CAR-T cell) therapy in T lymphocytes...
Autores principales: | Xia, Baijin, Lin, Keming, Wang, Xuemei, Chen, FeiLi, Zhou, Mo, Li, Yuzhuang, Lin, Yingtong, Qiao, Yidan, Li, Rong, Zhang, Wanying, He, Xin, Zou, Fan, Li, Linghua, Lu, Lijuan, Chen, Cancan, Li, WenYu, Zhang, Hui, Liu, Bingfeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427987/ https://www.ncbi.nlm.nih.gov/pubmed/37593111 http://dx.doi.org/10.1016/j.omto.2023.07.007 |
Ejemplares similares
-
Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins
por: Qiao, Yidan, et al.
Publicado: (2023) -
Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56
por: Zou, Fan, et al.
Publicado: (2019) -
Identification of CD98 as a Novel Biomarker for HIV-1 Permissiveness and Latent Infection
por: Zhang, Wanying, et al.
Publicado: (2022) -
The Application of Nanobody in CAR-T Therapy
por: Bao, Chaolemeng, et al.
Publicado: (2021) -
Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells
por: Wang, Hongxia, et al.
Publicado: (2021)